ES2158109T3 - Nuevo derivado de indano fusionado y sal del mismo farmaceuticamente aceptable. - Google Patents

Nuevo derivado de indano fusionado y sal del mismo farmaceuticamente aceptable.

Info

Publication number
ES2158109T3
ES2158109T3 ES95918733T ES95918733T ES2158109T3 ES 2158109 T3 ES2158109 T3 ES 2158109T3 ES 95918733 T ES95918733 T ES 95918733T ES 95918733 T ES95918733 T ES 95918733T ES 2158109 T3 ES2158109 T3 ES 2158109T3
Authority
ES
Spain
Prior art keywords
replaced
group
ring
sub
low
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95918733T
Other languages
English (en)
Inventor
Shinji Okazaki
Tetsuji Asao
Motoji Wakida
Keisuke Ishida
Masato Washinosu
Teruhiro Utsugi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taiho Pharmaceutical Co Ltd
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2158109T3 publication Critical patent/ES2158109T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UN DERIVADO DE INDANO FUNDIDO REPRESENTADO POR LA FORMULA GENERAL (1), UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, Y UN FARMACO ANTITUMOR, EN DONDE EL ANILLO A REPRESENTA UN ANILLO DE BENCENO O NAFTALENO OPCIONALMENTE SUSTITUIDO, O UN ANILLO DE BENCENO CON UN GRUPO ALQUILENODIOXI BAJO; EL ANILLO B REPRESENTA UN ANILLO DE BENCENO QUE PUEDE SER SUSTITUIDO O QUE TIENE UN GRUPO DE ALQUILENODIOXI BAJO; Y REPRESENTA -N=CR- O -CR=N-; R REPRESENTA -NR{SUB,1}R{SUB,2}, -OR{SUB,3} O UN GRUPO HETEROCICLICO NITROGENOSO OPCIONALMENTE SUSTITUIDO; R{SUB,1} Y R{SUB,2} SON EL MISMO O DIFERENTE EL UNO DEL OTRO Y CADA UNO REPRESENTA HIDROGENO, FENILO, UN GRUPO HETEROCICLICO NITROGENOSO OPCIONALMENTE SUSTITUIDO, O UN GRUPO DE ALQUILO BAJO QUE PUEDE SER SUSTITUIDO POR AL MENOS UN SUSTITUYENTE SELECCIONADO DEL GRUPO QUE CONSTA DE AMINO OPCIONALMENTE SUSTITUIDO, ALCOXI BAJO, FENILO, UN GRUPO HETEROCICLICO NITROGENOSO, UN GRUPO DE OXIDO DE AMINO SUSTITUIDO POR ALQUILO BAJO, E HIDROXI; Y R{SUB,3} REPRESENTA ALQUILO BAJO QUE PUEDE SER SUSTITUIDO POR AMINO SUSTITUIDO, CON TAL DE QUE SEA EXCLUIDO EL CASO DONDE R REPRESENTE UN GRUPO HETEROCICLICO NITROGENOSO OPCIONALMENTE SUSTITUIDO Y LOS ANILLOS A Y B REPRESENTEN CADA UNO UN ANILLO DE BENCENO NO SUSTITUIDO.
ES95918733T 1994-05-20 1995-05-18 Nuevo derivado de indano fusionado y sal del mismo farmaceuticamente aceptable. Expired - Lifetime ES2158109T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP10719094 1994-05-20

Publications (1)

Publication Number Publication Date
ES2158109T3 true ES2158109T3 (es) 2001-09-01

Family

ID=14452758

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95918733T Expired - Lifetime ES2158109T3 (es) 1994-05-20 1995-05-18 Nuevo derivado de indano fusionado y sal del mismo farmaceuticamente aceptable.

Country Status (21)

Country Link
US (3) US5733918A (es)
EP (1) EP0713870B1 (es)
KR (1) KR100190732B1 (es)
CN (1) CN1131216C (es)
AT (1) ATE203236T1 (es)
AU (1) AU685631B2 (es)
CA (1) CA2167382C (es)
DE (1) DE69521770T2 (es)
DK (1) DK0713870T3 (es)
ES (1) ES2158109T3 (es)
FI (1) FI111721B (es)
GR (1) GR3036795T3 (es)
HU (1) HU218308B (es)
IL (1) IL113778A (es)
NO (1) NO305555B1 (es)
NZ (1) NZ285448A (es)
PT (1) PT713870E (es)
RU (1) RU2124017C1 (es)
TW (1) TW440562B (es)
WO (1) WO1995032187A1 (es)
ZA (1) ZA954077B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3141148B2 (ja) * 1995-08-08 2001-03-05 大鵬薬品工業株式会社 縮合インダン誘導体及びその塩
DE19538088A1 (de) * 1995-10-13 1997-04-17 Bernd Prof Dr Clement Phenanthridinderivate und ihre Herstellung
US20030096833A1 (en) * 2001-08-31 2003-05-22 Jagtap Prakash G. Substituted ideno[1,2-c]isoquinoline derivatives and methods of use thereof
US6956035B2 (en) * 2001-08-31 2005-10-18 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
CA2461572C (en) * 2001-10-05 2011-02-15 F. Hoffmann-La Roche Ag Polycyclic compounds having anti-tumor activity
US6946472B2 (en) * 2002-04-30 2005-09-20 Hoffman-La Roche Inc. Polycyclic compounds exhibiting anti-tumor activities
CL2004000366A1 (es) * 2003-02-26 2005-01-07 Pharmacia Corp Sa Organizada B USO DE UNA COMBINACION DE UN COMPUESTO DERIVADO DE PIRAZOL INHIBIDOR DE QUINASA p38, Y UN INHIBIDOR DE ACE PARA TRATAR DISFUNCION RENAL, ENFERMEDAD CARDIOVASCULAR Y VASCULAR, RETINOPATIA, NEUROPATIA, EDEMA, DISFUNCION ENDOTELIAL O INSULINOPATIA.
KR20050118169A (ko) * 2003-02-28 2005-12-15 이노텍 파마슈티컬스 코포레이션 사환식 벤즈아미드 유도체 및 이것의 사용 방법
CN101014343A (zh) * 2004-02-26 2007-08-08 伊诺泰克制药公司 四环内酰胺衍生物及其应用
CA2557547A1 (en) * 2004-02-26 2005-09-09 Inotek Pharmaceuticals Corporation Isoquinoline derivatives and methods of use thereof
WO2006009718A2 (en) * 2004-06-16 2006-01-26 Inotek Pharmaceuticals Corporation Methods for treating or preventing erectile dysfunction or urinary incontinence
JP2008531590A (ja) * 2005-02-24 2008-08-14 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ カリウムイオンチャンネル開口薬としての新規なキノリン誘導体
JP2008531563A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環スルホンアミド化合物およびこれらの使用法
JP2008531562A (ja) * 2005-02-25 2008-08-14 イノテック ファーマシューティカルズ コーポレイション 四環アミノ化合物および四環カルボキサミド化合物およびこれらの使用法
AU2006219022A1 (en) * 2005-02-25 2006-09-08 Inotek Pharmaceuticals Corporation Isoqunoline Compounds and methods of use thereof
RU2008110955A (ru) * 2005-08-24 2009-09-27 Инотек Фармасьютикалз Корпорейшн (Us) Инденоизохинолиноновые аналоги и способы их применения
KR20090115879A (ko) * 2007-02-28 2009-11-09 이노텍 파마슈티컬스 코포레이션 인데노이소퀴놀리논 유사체와 이의 이용 방법
CN103102304B (zh) * 2013-01-19 2015-03-11 安徽师范大学 N-磺酰基取代四氢异喹啉衍生物的制备方法
BR112016003247B1 (pt) 2013-08-22 2022-05-10 Taiho Pharmaceutical Co., Ltd Composto substituído por quinolina, composição farmacêutica compreendendo o referido composto e seu uso
MX390435B (es) 2016-10-31 2025-03-20 Taiho Pharmaceutical Co Ltd Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.
AU2018325819B2 (en) 2017-09-01 2024-02-01 Taiho Pharmaceutical Co., Ltd. Exon 18 and/or exon 21 mutant EGFR selective inhibitor
EP4086290A1 (en) * 2021-05-04 2022-11-09 SHPP Global Technologies B.V. Capped bisphenol polyindane oligomer and composition, method of manufacture, and articles made therefrom

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60169482A (ja) * 1984-02-14 1985-09-02 Mitsubishi Chem Ind Ltd アミノ化フタライド−イソキノリン類の製法
JPH0633263B2 (ja) * 1985-05-27 1994-05-02 鐘淵化学工業株式会社 ７−ヒドロキシグアニン誘導体及びその製造方法並びにそれを有効成分とする抗腫瘍剤
SU1574598A1 (ru) * 1987-11-03 1990-06-30 Институт Химической Кинетики И Горения Со Ан Ссср Способ получени 4-диалкиламино-2-алкил(или фенил)нафто[2,3- @ ]хинолин-7,12-дионов
US5223506A (en) * 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds

Also Published As

Publication number Publication date
KR960703864A (ko) 1996-08-31
ATE203236T1 (de) 2001-08-15
HU218308B (en) 2000-07-28
NO305555B1 (no) 1999-06-21
KR100190732B1 (ko) 1999-06-01
IL113778A (en) 1999-09-22
IL113778A0 (en) 1995-08-31
NZ285448A (en) 1997-11-24
CA2167382A1 (en) 1995-11-30
DE69521770D1 (de) 2001-08-23
CN1130903A (zh) 1996-09-11
EP0713870A1 (en) 1996-05-29
DE69521770T2 (de) 2002-05-23
EP0713870B1 (en) 2001-07-18
FI960280A0 (fi) 1996-01-19
PT713870E (pt) 2001-11-30
US6028079A (en) 2000-02-22
US5733918A (en) 1998-03-31
WO1995032187A1 (en) 1995-11-30
FI960280A7 (fi) 1996-03-18
AU2454295A (en) 1995-12-18
RU2124017C1 (ru) 1998-12-27
TW440562B (en) 2001-06-16
FI111721B (fi) 2003-09-15
DK0713870T3 (da) 2001-09-24
NO960239D0 (no) 1996-01-19
HUT75651A (en) 1997-05-28
US5710162A (en) 1998-01-20
EP0713870A4 (en) 1996-12-18
ZA954077B (en) 1996-01-19
AU685631B2 (en) 1998-01-22
CN1131216C (zh) 2003-12-17
NO960239L (no) 1996-03-18
CA2167382C (en) 1999-08-31
GR3036795T3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
CZ284872B6 (cs) Cyklické močoviny a jejich analogy a farmaceutické přípravky na jejich bázi
DOP2000000070A (es) Piridinas y piridacinas sustituidas con actividad de inhibición de angiogénesis
PA8538201A1 (es) Inhibidores de piridina de metaloproteinasas de la matriz
UA39099C2 (uk) Циклічні азотовмісні похідні, суміш їх ізомерів або окремі ізомери, або їх солі
DOP2002000328A (es) Pirimidinas inhibidoras de metaloproteinasas de matriz
MX9201637A (es) Derivados de tiazolidindiona, proceso para su produccion y composicion farmaceutica que los contiene.
ATE184194T1 (de) Immunsuppressive und antiallergische verbindungen; z.b. n-(3-oxohexanoyl)- homoserinlacton
AR003937A1 (es) Compuesto ciclico que tiene efecto antagonico al receptor de taquiquinina, proceso para producirlo y composicion farmaceutica que lo contiene.
ATE217629T1 (de) Phosphonooxymethyl oder methylthiomethylether von taxanderivaten als antitumormittel
BR9810137A (pt) Composto, composição farmacêutica e método de tratamento ou prevenção de uma desordem tromoboembólica
ES2156933T3 (es) Derivados triciclicos de benzazepina y benzotiazepina.
TW256832B (es)
ES2095942T3 (es) Derivados de bencenoacetamida inhibidores del vih.
ES2195933T3 (es) Nuevos derivados de flavonas, xantonas y cumarinas.
KR960702830A (ko) 방사선 보호제로서의 N-알킬티오 폴리아민 유도체(N-Alkylthio polyaine derivatives as radioprotective agents)
ATE251624T1 (de) Granulatimide-derivate zur behandlung von krebs
DK0713870T3 (da) Nyt kondenseret indanderivat og farmaceutisk acceptabelt salt deraf
MX9301240A (es) Derivados heterociclicos de cetona, condensados, metodo para su produccion y composicion farmaceutica que los contiene.
NO302072B1 (no) Azabicyklo-arylacetylen- og -arylenyn-oksimer som cholinerge midler og preparater inneholdende slike
CO4290299A1 (es) Derivados de 1,5-benzodiazepina
MX9306679A (es) Penems 6-(metilen-sustituidos), derivados de los mismos, proceso para su preparacion y composicion farmaceutica que los contiene.
ES396388A1 (es) Procedimiento para la obtencion de compuestos de acido 7- amino-cef-3-em-4-carboxilico.
ES2180977T3 (es) Un derivado de 1-metilcarbapenem.
CO4410199A1 (es) Procedimiento estereoselectivo para producir derivados de dihidro-2,3-benzodiacepina
WO2001022951A3 (en) Use of substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives for the treatment of multiple sclerosis

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 713870

Country of ref document: ES